Want to see JP:4597 full AI Analyst Report?
4597 Stock Chart & Stats
¥27.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥27.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥21.00 - ¥42.00
Previous CloseN/A
Volume8.51M
Average Volume (3M)41.98M
Market Cap
¥7.92B
Enterprise Value¥5.89K
Total Cash (Recent Filing)¥1.29B
Total Debt (Recent Filing)¥78.00M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Bulls Say, Bears Say
Bulls Say
Conservative LeverageTTM debt-to-equity of about 0.05 limits interest and refinancing pressure, giving Solasia more flexibility to fund oncology development. This is a meaningful buffer, although it does not offset continuing operating losses and cash consumption.
Improved Gross MarginTTM gross margin improved to about 41% from negative in 2024, showing that product economics have strengthened at the gross-profit level. Sustained improvement could support future operating leverage, though overhead still leaves margins deeply negative.
Partner-Based Oncology ModelAn oncology and supportive-care focus addresses recurring clinical needs, while licensing and collaborations can share development, regulatory and commercialization burdens. A broader partner network could create milestone, royalty or profit-share income without requiring a fully internal sales infrastructure.
Bears Say
Persistent Cash BurnNegative operating and free cash flow across all reported periods indicates that the business is not self-funding. Continued cash burn raises the likelihood of future financing, potential dilution and reduced capacity to advance the development pipeline.
Deep Operating LossesRecurring losses and a deeply negative net margin show that current revenue is insufficient to cover the company’s cost base. Without sustained revenue growth or material cost restructuring, Solasia has not demonstrated a credible near-term path to breakeven.
Revenue Volatility And Equity ErosionRecent revenue contraction limits operating leverage, while cumulative losses have reduced the equity cushion. If weak sales and losses persist, the company’s financial resilience may deteriorate despite currently low leverage and increase dependence on external capital.
Solasia Pharma KK News
4597 FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was ¥21.00 and its highest was ¥42.00 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is ¥7.92B.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is Nov 16, 2026 which is in 80 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on Aug 13, 2026. The company reported -¥1 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -¥1 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in JP:4597
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―